Patient P-03110
Therapy response
Declining
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
67%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S15
- Day 58 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 63 GI-04 recommended — GI Support Protocol GI-04
- Day 64 Patient accepted — Started GI-04 in the companion
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient accepted — Started SC-12 in the companion
- Day 72 GI symptom burden −37% vs expected — GI Support Protocol GI-04
- Day 72 GI symptom burden −22% vs expected — Supportive Compound SC-12
- Day 78 Tolerance state changed — Unstable → Improving
- Day 78 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 58.
Primary contributors, last 14 days
- GI instability+14
- Nutritional resilience-7
- Inflammatory activity+5
- Toxicity+4
- Treatment adherence-3
What helped?
- GI Support Protocol GI-04Day 63Result: symptom burden −37%
- Supportive Compound SC-12Day 65Result: symptom burden −22%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
64%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log2.9/10
worsening · -0.8 vs previous 14 d
Stress level
Daily log6/10
worsening · +0.3 vs previous 14 d
Pessimism score
Daily log6/10
worsening · +0.3 vs previous 14 d
Sleep quality
Wearable27.6/100
worsening · -4.8 vs previous 14 d
Libido
Daily log3/10
worsening · -0.3 vs previous 14 d
HRV
Wearable49.4 ms
stable · -1.4 vs previous 14 d
Toxicity
Blood37.2/100
worsening · +8.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 42 from the failing basin, 46 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 11 similar · onset 3 d · confidence 64%
- DT-01 Dosing / Timing Recommendation82% improved among 11 similar · onset 5 d · confidence 64%
- NP-02 Dietary Support Protocol57% improved among 14 similar · onset 10 d · confidence 64%
- More proteinGI -4 next day on high-intake days · n 21
Would not help
- AD-05 Adherence Supportonly 27% improved among 11 similar
- Keep fat lowGI +3.6 next day on high-intake days · n 28
- Keep histamine lowGI +3.6 next day on high-intake days · n 26
- Keep alcohol lowGI +2.2 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4supporter · 95%
- Dietary fat load+3.6detractor · 95%
- Histamine load+3.6detractor · 95%
- Alcohol+2.2detractor · 60%
- Lactose+0.9no signal · 24%
- Caffeine+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.8 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 36/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 77 bpm
- Wearable1,131 steps/day
- WearableShort sleep window
- Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 43
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 36/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 6.2 h
- Steps
- 2,166
- Resting HR
- 75 bpm
Daily log: GI score 50, nutritional resilience 47, adherence 56.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.